CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000M vs $409.235B Est

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

CVS Health (NYSE:CVS) raises FY2026 Adj EPS guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 analyst estimate. FY2026 Revenue expected to be more than $414.000M vs $409.235B Est